Abstract
MHC-specific Natural Killer inhibitory receptors display a conserved and fundamental function in the regulation of NK-mediated cytolysis. Their importance is substantiated by the fact that during speciation different molecular receptor structures have evolved to maintain inhibitory regulation of NK cells. The information gained during these last twenty years begins to be fruitfully used in the therapy of leukemias, but a lot has to be still done. In particular, we need to understand the role of activating KIR and their ligand(s), since their role in the course of different viral diseases is still intriguing.
Keywords: Killer inhibitory receptor, human leukocyte antigen, activating receptors, sialoadhesin
Current Pharmaceutical Design
Title: NK Cell Receptors and Their Interactions with MHC
Volume: 15 Issue: 28
Author(s): Roberto Biassoni, Elisabetta Ugolotti and Andrea De Maria
Affiliation:
Keywords: Killer inhibitory receptor, human leukocyte antigen, activating receptors, sialoadhesin
Abstract: MHC-specific Natural Killer inhibitory receptors display a conserved and fundamental function in the regulation of NK-mediated cytolysis. Their importance is substantiated by the fact that during speciation different molecular receptor structures have evolved to maintain inhibitory regulation of NK cells. The information gained during these last twenty years begins to be fruitfully used in the therapy of leukemias, but a lot has to be still done. In particular, we need to understand the role of activating KIR and their ligand(s), since their role in the course of different viral diseases is still intriguing.
Export Options
About this article
Cite this article as:
Biassoni Roberto, Ugolotti Elisabetta and De Maria Andrea, NK Cell Receptors and Their Interactions with MHC, Current Pharmaceutical Design 2009; 15 (28) . https://dx.doi.org/10.2174/138161209789105225
DOI https://dx.doi.org/10.2174/138161209789105225 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Necrotizing Enterocolitis: Clinical Features, Histopathological Characteristics,
and Genetic Associations
Current Pediatric Reviews Multicolor-FISH Approaches for the Characterization of Human Chromosomes in Clinical Genetics and Tumor Cytogenetics
Current Genomics Recent Advances in Small Molecule Prodrugs for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry DNA Methylation Based Biomarkers in Non-Invasive Cancer Screening
Current Molecular Medicine Anticancer Agents: VTA or VDA
Current Bioactive Compounds Noscapine and its Analogs as Chemotherapeutic Agent: Current updates
Current Topics in Medicinal Chemistry Drugs Acting on the Beta Isoform of Human Topoisomerase II (p180)
Current Medicinal Chemistry - Anti-Cancer Agents Natural Products Targeting Cancer Stem Cells: A Revisit
Current Medicinal Chemistry MicroRNAs and Cancer: Towards a Personalized Medicine
Current Molecular Medicine Myeloid Malignancies and the Marrow Microenvironment: Some Recent Studies in Patients with MDS
Current Cancer Therapy Reviews Stent-Based Delivered Anti-Proliferative Drugs in the Prevention of Coronary Stent Restenosis
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Small Molecule Toxins Targeting Tumor Receptors
Current Pharmaceutical Design Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
Anti-Cancer Agents in Medicinal Chemistry Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Current Drug Targets Successful Combination of Sequential Gene Therapy and Rescue Allo-HSCT in Two Children with X-CGD - Importance of Timing
Current Gene Therapy Teratogenic Activity of HDAC Inhibitors
Current Pharmaceutical Design Editorial (Hot Topic: Modifying Cardiovascular Risk Factors: New Markers of Cardiovascular Damage)
Current Pharmaceutical Design Targeting Cancer and Neuropathy with Histone Deacetylase Inhibitors:Two Birds with One Stone?
Current Cancer Drug Targets Management of Inflammatory Bowel Disease Using Stem Cell Therapy
Current Stem Cell Research & Therapy Intercalation of Erlotinib and Pemetrexed in the Treatment of Non-Small Cell Lung Cancer
Current Drug Targets